TD Cowen Maintained a Hold Rating on Myriad Genetics (MYGN)

Myriad Genetics, Inc. (NASDAQ:MYGN) is one of the Best 52-Week Low Penny Stocks to Buy Now. On August 5, Daniel Brennan from TD Cowen maintained a Hold rating on Myriad Genetics, Inc. (NASDAQ:MYGN) with a $6 price target.

The rating follows the company’s fiscal second quarter 2025 earnings release, where the company posted a strong quarter after a weaker first quarter for 2025. Myriad Genetics, Inc. posted revenue of $213.10 million, reflecting around 1% year-over-year growth and ahead of expectations by $10.8 million. The EPS of $0.05 also exceeded expectations by $0.06.

TD Cowen Maintained a Hold Rating on Myriad Genetics (MYGN)

A medical professional in a laboratory analyzing the outcomes of a molecular diagnostic test.

Brennan noted that this was mainly due to a solid performance in Hereditary Cancer Testing and GeneSight. However, he highlighted that the Prenatal segment remains weak, and the outlook for the second half of 2025 hints at a possible decline in year-over-year growth. The company also faces challenges from the loss of a GeneSight contract and issues with electronic medical records affecting volumes, thereby resulting in a cautious rating from the analyst.

Myriad Genetics, Inc. is a genetic testing and precision medicine company that develops genetic tests to help assess disease risk and guide treatment decisions.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

This article is originally published at Insider Monkey.